Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21995763 | 0.89 | ADRB1 (0.52) | HTR6HTR7HTR1AHTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL21995940 | 0.87 | LMNA (0.53) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL2348878 | 0.79 | ADRB1 (0.53) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL30839762 | 0.79 | ADRB1 (0.53) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL4688382 | 0.79 | ADRB1 (0.53) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL21744394 | 0.78 | HTR2C (0.54) | HTR6HTR7HTR1AHTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL5247444 | 0.78 | ADRB1 (0.51) | HTR6HTR7HTR1AHTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL30183267 | 0.78 | ADRB1 (0.51) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL5371599 | 0.78 | ADRB1 (0.51) | HTR6HTR7HTR1AHTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL8572545 | 0.78 | ADRB1 (0.51) | HTR6HTR7HTR1AHTR2AHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881841-B2 | Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | Takeuchi, Tsutomu (JP) | 2005-04-19 | — | — | US | claimed |
| US-20040029895-A1 | Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | TAKAYANAGI, HIROAKI (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1336608-A1 | DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-08-20 | — | — | EP | claimed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | STATE UNIVERSITY (US) | 2013-11-21 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-7968539-B2 | reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011034971-A1 | MODIFIED FLUOROQUINOLONE COMPOUNDS AND METHODS OF USING THE SAME | DESIGNMEDIX, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| EP-1336608-A4 | DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES | POLA CHEM IND INC (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20080214570-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2002042284-A1 | DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2002-05-30 | — | — | WO | disclosed |
| EP-0603404-B1 | PROCESS FOR PRODUCING GLYCIDE DERIVATIVE | MITSUI CHEMICALS INC (JP) | 1999-03-17 | — | — | EP | disclosed |
| US-5463061-A | Process for production of glycide derivative | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-10-31 | — | — | US | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0603404-A1 | PROCESS FOR PRODUCING GLYCIDE DERIVATIVE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1994-06-29 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029895-A1 | Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | ABCC1, ABCB1, SLC11A2 | HTR6 2144/4885HTR7 2579/4885HTR1A 3114/4885 |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | HTR6 2562/4885HTR7 1788/4885HTR1A 3288/4885 |
| US-20080214570-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | HTR6 95/4885HTR7 335/4885HTR1A 244/4885 |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | HTR6 2562/4885HTR7 1788/4885HTR1A 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.